How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


A Novel Marker for Brown Fat Activity - Exosomal microRNA-92 in serum reflects brown fat activity

Organization name

PROvendis GmbH



Brown adipose tissue (BAT)
is a special type of fat, which regulates the body temperature by fatty acid oxidation. High BAT activity is involved in leanness, whereas obesity comes along with a reduced activity of BAT. Therefore, the measurement of BAT activity is an important diagnostic parameter for various weight-related pathological conditions including diabetes, but was so far a complicated matter to measure. The current procedure utilizes glucose-based, radioactive tracer, positron-emission-tomographie combined with computer-tomography and requires pre-treatment of the patients by cold exposure.

The present invention is a technology that significantly simplifies the measurement of BAT by PCR-based quantification of exosomal microRNA-92a in serum. Exosomal miR-92a levels inversely correlate with BAT activity. This novel method is as the first of its kind qualified to routinely measure the BAT activity in large cohorts of patients.

Commercial Opportunities

The measurement of BAT activity is not only important in the diagnosis and treatment of weight-related diseases, but is also a screening tool for the development of drugs that regulate the BAT activity. Such drugs are of use in pathological leanness (e.g. cachexia), obesity and other metabolic diseases.

Current Status

The invention has been validated by studies in mice and man.

On behalf of the University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development. In case of interest we will be pleased to inform you about the patent status.

Relevant Publications

Chen J, Buyel JJ, Hanssen MJW, Siegel F, Pan R, Naumann J, Schell M, van der Lans A, Schlein C, Froehlich H, Heeren J, Virtanen KA, van Marken Lichtenbelt W, Pfeifer A. Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. Nature Communications; DOI: 10.1038/ncomms11420

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries